- Home
- PFC vs ETNB Comparison
PFC vs ETNB Comparison
Compare PFC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFC
- ETNB
- Stock Information
- Founded
- PFC 1920
- ETNB 2018
- Country
- PFC United States
- ETNB United States
- Employees
- PFC N/A
- ETNB N/A
- Industry
- PFC Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- PFC Finance
- ETNB Health Care
- Exchange
- PFC Nasdaq
- ETNB Nasdaq
- Market Cap
- PFC 897.4M
- ETNB 933.6M
- IPO Year
- PFC N/A
- ETNB 2019
- Fundamental
- Price
- PFC $26.30
- ETNB $8.01
- Analyst Decision
- PFC Hold
- ETNB Buy
- Analyst Count
- PFC 5
- ETNB 7
- Target Price
- PFC $23.33
- ETNB $30.33
- AVG Volume (30 Days)
- PFC 146.1K
- ETNB 1.3M
- Earning Date
- PFC 01-21-2025
- ETNB 11-07-2024
- Dividend Yield
- PFC 4.74%
- ETNB N/A
- EPS Growth
- PFC N/A
- ETNB N/A
- EPS
- PFC 1.97
- ETNB N/A
- Revenue
- PFC $245,857,000.00
- ETNB N/A
- Revenue This Year
- PFC N/A
- ETNB N/A
- Revenue Next Year
- PFC $7.24
- ETNB N/A
- P/E Ratio
- PFC $13.34
- ETNB N/A
- Revenue Growth
- PFC N/A
- ETNB N/A
- 52 Week Low
- PFC $18.63
- ETNB $6.43
- 52 Week High
- PFC $29.63
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- PFC 42.16
- ETNB 48.30
- Support Level
- PFC $25.41
- ETNB $6.43
- Resistance Level
- PFC $28.29
- ETNB $8.10
- Average True Range (ATR)
- PFC 0.81
- ETNB 0.52
- MACD
- PFC -0.26
- ETNB 0.01
- Stochastic Oscillator
- PFC 25.14
- ETNB 76.33
About PFC Premier Financial Corp.
Premier Financial Corp is a financial holding company that operates as a community banking and financial services corporation. It offers a broad range of financial services through its subsidiaries including checking accounts, savings accounts, certificates of deposit, real estate mortgage loans, commercial loans, consumer loans, home equity loans, and trust and wealth management services.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).